Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Hyper-reactions to radiotherapy

ECCO 15 - ESMO 34

Published: 3 Nov 2009

Views: 13785

Rating:

Save

Dirk De Ruysscher - University Hospital Maastricht, Netherlands

Dirk De Ruysscher, from the University Hospital Maastricht, Netherlands, discusses his work studying the genetics of patients and predicting reaction to radiotherapy, in order to improve efficiency. Talking at ECCO 15- ESMO 34, Berlin 2009.

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

The evolving paradigm in management of Multiple Myeloma

D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

The evolving paradigm in management of Multiple Myeloma ( D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC...

Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA

$A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients ( Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA )$

Precision oncology: Present and future in breast cancer

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Precision oncology: Present and future in breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

Abiraterone acetate/prednisone + apalutimide and ADT with post-op SRT may...

Prof Paul L Nguyen - Dana-Farber Cancer Institute, Boston, USA

Abiraterone acetate/prednisone + apalutimide and ADT with post-op SRT may improve PFS and MFS after prostatectomy ( Prof Paul L Nguyen - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer